Division of Endocrinology, Metabolism and Nutrition, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Curr Opin Endocrinol Diabetes Obes. 2010 Dec;17(6):561-7. doi: 10.1097/MED.0b013e32834041d4.
The study of phosphorus physiology and investigations into clinical disorders of phosphorus metabolism has blossomed over the past decade. Recent work has confirmed and further extended our knowledge of basic mechanisms of phosphorus metabolism.
This review will focus on FGF-23 and Klotho, and on the recent further dissection of their roles in phosphorus and skeletal metabolism. Additionally, this review will detail recent studies that implicate a role for these phosphaturic and vitamin D regulating factors in extraskeletal calcification, including that occurring in soft tissue and vascular beds.
These findings in total provide fertile ground for investigations into the cause and treatment of abnormal skeletal and extraskeletal calcification in patients with inherited hypophosphatemic disorders. More importantly, and certainly with wider potential clinical application, these studies likewise imply a role for these factors in the pathogenesis of accelerated cardiovascular disease that occurs in patients with the most common hyperphosphatemic disorder, chronic kidney disease. Future studies are needed to confirm a harmful or possibly even beneficial role for FGF-23 and other factors in these disease states, and to determine whether therapeutic manipulation of these factors does truly affect clinical outcomes in patients with hypophosphatemia and hyperphosphatemia.
在过去的十年中,磷生理学的研究和临床磷代谢紊乱的调查蓬勃发展。最近的工作证实并进一步扩展了我们对磷代谢基本机制的认识。
本综述将重点介绍 FGF-23 和 Klotho,并详细介绍它们在磷和骨骼代谢中的作用的最新进一步剖析。此外,本综述将详细介绍最近的研究,这些研究表明这些排磷和维生素 D 调节因子在骨骼外钙化中的作用,包括发生在软组织和血管床中的钙化。
这些发现为研究遗传性低磷血症患者骨骼和骨骼外异常钙化的原因和治疗提供了肥沃的基础。更重要的是,这些研究同样暗示了这些因素在最常见的高磷血症性疾病——慢性肾脏病患者加速心血管疾病发病机制中的作用,具有更广泛的潜在临床应用。未来的研究需要证实 FGF-23 和其他因素在这些疾病状态中的有害或可能有益的作用,并确定对这些因素的治疗干预是否确实影响低磷血症和高磷血症患者的临床结局。